KW
Kwangdong Healthbio Co., Ltd.
086220 | KO
Overview
Corporate Details
- ISIN(s):
- KR7086220001
- LEI:
- Country:
- South Korea
- Address:
- 충청북도 청원군 오창읍 양청송대길 39(송대리), 오창읍
- Website:
- http://www.kd-healthbio.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-04 00:00 |
Report Publication Announcement
기업설명회(IR)개최결과
|
Korean | 6.7 KB | ||
| 2025-05-21 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.1 KB | ||
| 2025-03-25 00:00 |
AGM Information
정기주주총회결과
|
Korean | 15.2 KB | ||
| 2025-03-17 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 9.6 KB | ||
| 2025-03-17 00:00 |
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
|
Korean | 436.1 KB | ||
| 2025-03-10 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 114.1 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 26.1 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 25.1 KB | ||
| 2025-02-25 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 8.4 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 28.6 KB | ||
| 2024-12-11 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.4 KB | ||
| 2024-10-30 00:00 |
Report Publication Announcement
기업설명회(IR)개최결과
|
Korean | 6.7 KB | ||
| 2024-10-14 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.0 KB | ||
| 2024-08-20 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 53.3 KB | ||
| 2024-08-19 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 53.6 KB |
Automate Your Workflow. Get a real-time feed of all Kwangdong Healthbio Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Kwangdong Healthbio Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kwangdong Healthbio Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops peptide therapeutics for blood disorders and inflammatory or immunomodulatory diseases.
United States of America
PTGX
United States of America
PTGX
Develops plant-cell-based protein therapies for rare diseases like Gaucher and Fabry.
United States of America
PLX
United States of America
PLX
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea
303360
South Korea
303360
Developing natural psilocybin therapies for anxiety and depression in palliative care.
United States of America
PBM
United States of America
PBM
Develops and commercializes pioneering medicines for patients with rare diseases.
United States of America
PTCT
United States of America
PTCT
Develops inhaled therapies for respiratory and CNS disorders using its iSPERSE™ technology.
United States of America
PULM
United States of America
PULM
Develops and commercializes innovative cancer therapeutics, with an approved drug and a clinical pipeline.
United States of America
PBYI
United States of America
PBYI
Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.
Poland
PUR
Poland
PUR
A clinical-stage biotherapeutics firm developing new medicines for devastating diseases.
United States of America
PRTC
United States of America
PRTC
Developing cancer therapies to overcome tumor immune evasion and drug resistance.
Israel
PPBT
Israel
PPBT